Fractalkine is a novel human adipochemokine associated with type 2 diabetes

Rachana Shah; Christine C. Hinkle; Jane F. Ferguson; Nehal N. Mehta; Mingyao Li; Liming Qu; Yun Lu; Mary E. Putt; Rexford S. Ahima; Muredach P. Reilly

doi:10.2337/db10-0956

Fractalkine is a novel human adipochemokine associated with type 2 diabetes

Rachana Shah, Christine C. Hinkle, Jane F. Ferguson, Nehal N. Mehta, Mingyao Li, Liming Qu, Yun Lu, Mary E. Putt, Rexford S. Ahima, Muredach P. Reilly

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

OBJECTIVE - Leukocyte infiltration of adipose is a critical determinant of obesity-related metabolic diseases. Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS - CX3CL1 mRNA and protein were quantified in subcutaneous adipose and blood during experimental human endotoxemia and in lean and obese human adipose. CX3CL1 cellular source was probed in human adipocytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in monocyte-adipocyte adhesion. The association of genetic variation in CX3CR1 with metabolic traits was determined in a community-based sample. Finally, plasma CX3CL1 levels were measured in a case-control study of type 2 diabetes. RESULTS - Endotoxemia induced adipose CX3CL1 mRNA (32.7-fold, P < 1 × 10^-5) and protein (43-fold, P = 0.006). Obese subjects had higher CX3CL1 levels in subcutaneous adipose compared with lean (0.420 ± 0.387 vs. 0.228 ± 0.187 ng/mL, P = 0.04). CX3CL1 was expressed and secreted by human adipocytes and stromal vascular cells. Inflammatory cytokine induction of CX3CL1 in human adipocytes (27.5-fold mRNA and threefold protein) was completely attenuated by pretreatment with a peroxisome proliferator-activated receptor-g agonist. A putative functional nonsynonymous single nucleotide polymorphism (rs3732378) in CX3CR1 was associated with adipose and metabolic traits, and plasma CX3CL1 levels were increased in patients with type 2 diabetes vs. nondiabetics (0.506 ± 0.262 vs. 0.422 ± 0.210 ng/mL, P < 0.0001). CONCLUSIONS - CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine system that modulates monocyte adhesion to adipocytes and is associated with obesity, insulin resistance, and type 2 diabetes. These data provide support for CX3CL1 as a diagnostic and therapeutic target in cardiometabolic disease.

Original language	English (US)
Pages (from-to)	1512-1518
Number of pages	7
Journal	Diabetes
Volume	60
Issue number	5
DOIs	https://doi.org/10.2337/db10-0956
State	Published - May 2011
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.2337/db10-0956

Cite this

@article{c25124caebc1422f8e3c215b8eca0440,

title = "Fractalkine is a novel human adipochemokine associated with type 2 diabetes",

abstract = "OBJECTIVE - Leukocyte infiltration of adipose is a critical determinant of obesity-related metabolic diseases. Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS - CX3CL1 mRNA and protein were quantified in subcutaneous adipose and blood during experimental human endotoxemia and in lean and obese human adipose. CX3CL1 cellular source was probed in human adipocytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in monocyte-adipocyte adhesion. The association of genetic variation in CX3CR1 with metabolic traits was determined in a community-based sample. Finally, plasma CX3CL1 levels were measured in a case-control study of type 2 diabetes. RESULTS - Endotoxemia induced adipose CX3CL1 mRNA (32.7-fold, P < 1 × 10-5) and protein (43-fold, P = 0.006). Obese subjects had higher CX3CL1 levels in subcutaneous adipose compared with lean (0.420 ± 0.387 vs. 0.228 ± 0.187 ng/mL, P = 0.04). CX3CL1 was expressed and secreted by human adipocytes and stromal vascular cells. Inflammatory cytokine induction of CX3CL1 in human adipocytes (27.5-fold mRNA and threefold protein) was completely attenuated by pretreatment with a peroxisome proliferator-activated receptor-g agonist. A putative functional nonsynonymous single nucleotide polymorphism (rs3732378) in CX3CR1 was associated with adipose and metabolic traits, and plasma CX3CL1 levels were increased in patients with type 2 diabetes vs. nondiabetics (0.506 ± 0.262 vs. 0.422 ± 0.210 ng/mL, P < 0.0001). CONCLUSIONS - CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine system that modulates monocyte adhesion to adipocytes and is associated with obesity, insulin resistance, and type 2 diabetes. These data provide support for CX3CL1 as a diagnostic and therapeutic target in cardiometabolic disease.",

author = "Rachana Shah and Hinkle, {Christine C.} and Ferguson, {Jane F.} and Mehta, {Nehal N.} and Mingyao Li and Liming Qu and Yun Lu and Putt, {Mary E.} and Ahima, {Rexford S.} and Reilly, {Muredach P.}",

year = "2011",

month = may,

doi = "10.2337/db10-0956",

language = "English (US)",

volume = "60",

pages = "1512--1518",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "5",

}

TY - JOUR

T1 - Fractalkine is a novel human adipochemokine associated with type 2 diabetes

AU - Shah, Rachana

AU - Hinkle, Christine C.

AU - Ferguson, Jane F.

AU - Mehta, Nehal N.

AU - Li, Mingyao

AU - Qu, Liming

AU - Lu, Yun

AU - Putt, Mary E.

AU - Ahima, Rexford S.

AU - Reilly, Muredach P.

PY - 2011/5

Y1 - 2011/5

N2 - OBJECTIVE - Leukocyte infiltration of adipose is a critical determinant of obesity-related metabolic diseases. Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS - CX3CL1 mRNA and protein were quantified in subcutaneous adipose and blood during experimental human endotoxemia and in lean and obese human adipose. CX3CL1 cellular source was probed in human adipocytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in monocyte-adipocyte adhesion. The association of genetic variation in CX3CR1 with metabolic traits was determined in a community-based sample. Finally, plasma CX3CL1 levels were measured in a case-control study of type 2 diabetes. RESULTS - Endotoxemia induced adipose CX3CL1 mRNA (32.7-fold, P < 1 × 10-5) and protein (43-fold, P = 0.006). Obese subjects had higher CX3CL1 levels in subcutaneous adipose compared with lean (0.420 ± 0.387 vs. 0.228 ± 0.187 ng/mL, P = 0.04). CX3CL1 was expressed and secreted by human adipocytes and stromal vascular cells. Inflammatory cytokine induction of CX3CL1 in human adipocytes (27.5-fold mRNA and threefold protein) was completely attenuated by pretreatment with a peroxisome proliferator-activated receptor-g agonist. A putative functional nonsynonymous single nucleotide polymorphism (rs3732378) in CX3CR1 was associated with adipose and metabolic traits, and plasma CX3CL1 levels were increased in patients with type 2 diabetes vs. nondiabetics (0.506 ± 0.262 vs. 0.422 ± 0.210 ng/mL, P < 0.0001). CONCLUSIONS - CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine system that modulates monocyte adhesion to adipocytes and is associated with obesity, insulin resistance, and type 2 diabetes. These data provide support for CX3CL1 as a diagnostic and therapeutic target in cardiometabolic disease.

AB - OBJECTIVE - Leukocyte infiltration of adipose is a critical determinant of obesity-related metabolic diseases. Fractalkine (CX3CL1) and its receptor (CX3CR1) comprise a chemokine system involved in leukocyte recruitment and adhesion in atherosclerosis, but its role in adipose inflammation and type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS - CX3CL1 mRNA and protein were quantified in subcutaneous adipose and blood during experimental human endotoxemia and in lean and obese human adipose. CX3CL1 cellular source was probed in human adipocytes, monocytes, and macrophages, and CX3CL1-blocking antibodies were used to assess its role in monocyte-adipocyte adhesion. The association of genetic variation in CX3CR1 with metabolic traits was determined in a community-based sample. Finally, plasma CX3CL1 levels were measured in a case-control study of type 2 diabetes. RESULTS - Endotoxemia induced adipose CX3CL1 mRNA (32.7-fold, P < 1 × 10-5) and protein (43-fold, P = 0.006). Obese subjects had higher CX3CL1 levels in subcutaneous adipose compared with lean (0.420 ± 0.387 vs. 0.228 ± 0.187 ng/mL, P = 0.04). CX3CL1 was expressed and secreted by human adipocytes and stromal vascular cells. Inflammatory cytokine induction of CX3CL1 in human adipocytes (27.5-fold mRNA and threefold protein) was completely attenuated by pretreatment with a peroxisome proliferator-activated receptor-g agonist. A putative functional nonsynonymous single nucleotide polymorphism (rs3732378) in CX3CR1 was associated with adipose and metabolic traits, and plasma CX3CL1 levels were increased in patients with type 2 diabetes vs. nondiabetics (0.506 ± 0.262 vs. 0.422 ± 0.210 ng/mL, P < 0.0001). CONCLUSIONS - CX3CL1-CX3CR1 is a novel inflammatory adipose chemokine system that modulates monocyte adhesion to adipocytes and is associated with obesity, insulin resistance, and type 2 diabetes. These data provide support for CX3CL1 as a diagnostic and therapeutic target in cardiometabolic disease.

UR - http://www.scopus.com/inward/record.url?scp=79959445914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959445914&partnerID=8YFLogxK

U2 - 10.2337/db10-0956

DO - 10.2337/db10-0956

M3 - Article

C2 - 21525510

AN - SCOPUS:79959445914

SN - 0012-1797

VL - 60

SP - 1512

EP - 1518

JO - Diabetes

JF - Diabetes

IS - 5

ER -

Fractalkine is a novel human adipochemokine associated with type 2 diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this